Brent Zettl, President and CEO, CanniMed Therapeutics Inc.(TSX:CMED) and Rob Duguid , Chief Investment Officer, PFM Capital Inc. joined Brady Fletcher, Managing Director, TSX Venture Exchange to open the market. CanniMed is a Canadian-based, international plant biopharmaceutical company with 15 years of pharmaceutical cannabis cultivation experience. The Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMedTherapeutics Inc., will commence trading on Toronto Stock Exchange on December 29, 2016. For more information, please visit www.cannimed.ca
Through its affiliation with the fund managers PFM Fund Operations, PFM Venture Capital, Prairie Ventures GP, TopSoil Farm Land Management, and TopSoil Farm Land Management (II), and doing business as PFM Capital ("PFM Capital" or "PFM"), PFM is a leading private equity investment firm in Saskatchewan. Founded in 1989 as a corporate finance company, PFM has been managing private equity and venture capital funds since 1993. This website does not represent an offering of securities. The information disclosed is incomplete and can be qualified in its entirety by each fund's most recent offering document or limited partnership agreement, obtainable free of charge by contacting PFM Capital Inc. The securities described herein are only available to eligible investors in Canada in accordance with applicable securities laws.